Mitochondrial genome lesions in the pathogenesis of sporadic Alzheimer's disease

Gerontology

Volumn 45, Issue 5, 1999, Pages 289-297

  Meier Ruge, W A ^a   Bertoni Freddari, C ^b  

^a University Medical School   (Switzerland)

^b Functional Genomics Center   (Italy)

Author keywords

amyloid generation; Alzheimer's disease; ATP; Experimental pharmacology; Mitochondrial genome lesions; Oxidative phosphorylation; Pathogenesis

Indexed keywords

ACETYL COENZYME A; ACETYLCHOLINE; ADENOSINE TRIPHOSPHATE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CHOLINE; CHOLINE ACETYLTRANSFERASE; FLUORODEOXYGLUCOSE F 18; GLUCOSE; MITOCHONDRIAL DNA; PROTEINASE;

ACETYLATION; ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; BRAIN METABOLISM; GENOME; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; MITOCHONDRIAL RESPIRATION; NERVE CELL; OXIDATIVE PHOSPHORYLATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SYNAPTIC MEMBRANE;

AGING; ALZHEIMER DISEASE; BRAIN; DNA, MITOCHONDRIAL; HUMANS; MUTATION;

EID: 0032839281     PISSN: 0304324X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000022104     Document Type: Article

References (96)

1. Calhoun ME, Wiederhold K-H, Abramowski D, Phinney AL, Probst A, Sturchler-Pierrat Ch, Staufenbiel M, Sommer B, Jucker M: Neuron loss in APP transgenic mice. Nature 1998;395: 755-756.
2. Geula CH, Wu CH-K, Saroff D, Lorenzo A, Yuan M, Yankner BA: Aging renders the brain vulnerable to amyloid β-protein neurotoxicity. Nature Med 1998;4:827-831.
3. Sinex ME, Merril CR: Alzheimer's disease. Down's syndrome and aging: The genetic approach. Ann NY Acad Sci 1982;396:3-13.
4. Chartier-Harlin MC, Crawford F, Houlden H, Warren A, Huges D. Fidani L, Goate A, Rossor M, Roques P, Hardy J, Mullan M: Early-onset Alzheimer's disease caused by mutation at codon 717 of the beta-amyloid precursor protein gene. Nature 1991;353:844-846.
5. Kovacs DM, Fausett HJ, Page KJ, Kim T-W, Moir RD, Merriam DE, Hollister RD, Hallmark OG, Mancini R, Felsenstein KM, Hyman BT, Tanzi RE, Wasco W: Alzheimer-associated prcsinilins 1 and 2: Neuronal expression in brain and localization to intracellular membranes in mammalian cells. Nature Med 1996; 2:224-229.
6. Lemere CA, Lopera F, Kosik KS, Lendon CL, Ossa J, Saido TC, Yamaguchi H, Ruiz A, Martinez A, Madrigal L, Hincapie L, Arango JC, Anthony DC, Koo EH, Goate AM, Selkoe DJ, Arango JC: The E280 A presenilin 1 Alzheimer mutation produces increased Aβ 42 deposition and severe cerebellar pathology. Nature Med 1996;1146-1150.
7. Soong NW, Hinton DR, Cortopassi G, Amheim N: Mosaicism for a specific somatic mitochondrial DNA mutation in adult human brain. Nature Genet 1992;2:318-328.
8. Wolozin B, Iwasaki K, Vito P, Ganjei JK, Lacana E, Sunderland T, Zhao B, Kusiak JW, Wasco W, D'Adamio LD: Participation of presenilin 2 in apoptosis: Enhanced basal activity conferred by an Alzheimer mutation, Science 1996;274:1710-1713.
9. Meier-Ruge W, Iwangoff P, Bertoni-Freddari C: What is primary and what secondary for amyloid in Alzheimer's disease. Ann NY Acad Sci 1994;719:230-237.
10. Scheuner D, Eckmann C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levdy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, Younkin S: Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increase in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nature Med 1996;2:864-870.
11. Baringa M: Is apoptosis key in Alzheimer's disease? Science 1998;281:1303-1304.
12. Cotman CW, Anderson AJ: A potential role for apoptosis in neurodegeneration and Alzheimer's disease. Mol Neurobiol 1995;10:19-45.
13. Green DR, Reed JC: Mitochondria and apoptosis. Science 1998;281:1309-1312.
14. Meier-Ruge WA, Bertoni-Freddari C: Pathogenesis of decreased glucose turnover and oxidative phosporylation in ischemic and traumainduced dementia of the Alzheimer type. Ann NY Acad Sci 1997;826:229-241.
15. Johns DR: The other human genome. Mitochondrial DNA and disease. Nature Med 1996: 2:1065-1068.
16. Pallotti F, Geneva ML, Pich MM, Zucchini C, Carraro S, Tesei M, Bovina C, Lenaz G: Mitochondrial dysfunction and brain disorder. Arch Gerontol Geriatr 1998;(suppl 6):385-392.
17. Wallace DC: Mitochondrial genetics: a paradigm for aging and degenerative diseases? Science 1992;256:628-632.
18. Redjems-Bennani N, Jeandel C, Lefebre E, Blain H, Vidailhet M, Guéant J-L: Abnormal substrate levels that depend upon mitochondrial function in cerebrospinal fluid from Alzheimer patients. Gerontology 1998;44:300-304.
19. Hoyer S: Abnormalities of glucose metabolism in Alzheimer's disease. Ann NY Acad Sci 1991; 640:53-58.
20. Kessler J, Herholz K, Grand M, Heiss WD: Impaired metabolic activation in Alzheimer's disease: A PET study during continuous visual recognition. Neuropsychologia 1991;29:229-243.
21. Meier-Ruge W, Bertoni-Freddari C: The significance of glucose turnover in the brain in the pathogenetic mechanisms of Alzheimer's disease. Rev Neurosci 1996;7:1-19.
22. Meier-Ruge W, Bertoni-Freddari C. Iwangoff P: Changes in brain glucose metabolism as a key to the pathogenesis of Alzheimer's disease. Gerontology 1994;40:246-252.
23. Kennedy AM, Frackowiak RSJ, Newman SK, Sloomfield PM. Seaward J, Roques P, Lewington G, Cunningham VJ, Rossor MN: Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease. Neurosci Let 1995;186:17-20.
24. Heiss WD, Szelies B, Kessler J, Herholz K: Abnormalities of energy metabolism in Alzheimer's disease studied with PET. Ann NY Acad Sci 1991;640:65-71.
25. Jagust WJ, Eberling JL, Richardson BC, Reed BR, Baker MG, Nordahl TE, Budinger T: The cortical topography of temporal lobe hypometabolism in early Alzheimer's disease. Brain Res 1993;629:189-198.
26. Jagust W, Frieland R, Budinger T, Koss E, Ober B: Longitudinal studies of regional cerebral metabolism in Alzheimer's disease. Neurology 1993;38:909-912.
27. Mielkc R, Schröder R, Fink GR, Kessler J, Herholz K, Heiss WD: Regional cerebral glucose metabolism and postmortem pathology in Alzheimer's disease. Acta Neuropathol 1996; 91:174-179.
28. Piert M, Koeppe RA, Giordani B, Berent S, Kuhl DE: Diminished glucose transport and phosphorylation in Alzheimer's disease determined by dynamic FDG-PET. J Nucl Med 1996;37:201-208.
29. Rapoport SJ, Honwitz B, Grady CL, Haxby JV, DeCarli C, Schapiro MB: Abnormal brain glucose metabolism in Alzheimer's disease, as measured by positron emission tomography. Adv Exp Med Biol 1991;291:321-248.
30. Decarli C, Grady CL, Clark CM, Katz DA, Brady DR, Murphy DG, Haxby JV, Salerno JA, Gilette JA, Gonzalez-Aviles A, Rapoport SJ: Comparison of positron emission tomography, cognition, and brain volume in Alzheimer's disease with and without severe abnormalities of white matter. J Neurol Ncurosurg Psychiatry 1996;60:158-167.
31. Duara P, Barker WW, Chang J, Yoshii F, Loewenstein DA, Pascal S: Viability of neocortical function shown in behavioral activation state PET studies in Alzheimer disease. J Cereb Blood Flow Metab 1992;12:927-934.
32. Erecinska M, Silver IA: ATP and brain functions. J Cereb Blood Flow Metab 1989;9:2-19.
33. Gur RC, Mozley LH, Mozley PD, Resnick SM, Karp JS, Alavi A, Arnold SE, Gur RE: Sex differences in regional cerebral glucose metabolism during a resting state. Science 1995;267: 528-531.
34. Slansky J, Herholz K, Pietrzyk U, Kessler J, Grond M, Mielke R, Heiss WD: Cognitive impairment in Alzheimer's disease correlates with ventricular width and atrophy-corrected cortical glucose metabolism. Neuroradiology 1995;37:270-277.
35. Bertoni-Freddari C, Fattoretti P, Casoli T, Meier-Ruge W, Ulrich J: Reactive capacities of the central nervous system in physiological aging and senile dementia of the Alzheimer type. Ann NY Acad Sci 1991;621:98-103.
36. Bertoni-Freddari C, Fattoretti P, Casoli T, Spagna C, Meier-Ruge W, Ulrich J: Morphological plasticity of synaptic mitochondria during aging. Brain Res 1993;628:193-200.
37. Bertoni-Freddari C, Fattoretti R, Paoloni R, Caselli U, Galeazzi L, Meier-Ruge W: Synaptic structural dynamics and aging. Gerontology 1996;42:170-180.
38. Bertoni-Freddari C, Fattoretti P, Casoli T, Pieroni M, Meier-Ruge W, Ulrich J: Neurobiology of the aging brain: Morphological alteration at synaptic regions. Arch Gerontol Geriatr 1991; 12:253-259.
39. Iwangoff P, Armbruster R, Enz A, Meier-Ruge W: Glycolytic enzymes from human autoptic brain cortex: Normal and demented cases. Mech Ageing Dev 1980;14:203-209.
40. Jendroska K, Poewe W, Daniel SE, Plucss J, Iwerssen-Schmidt H, Paulsen J, Barthel S, Schelosky L, Cervos-Navarro J, DcArmond SJ: Ischemic stress induces deposition of amyloid β immunoreactivity in human brain. Acta Neuropathol 1995;90:461-466.
41. Meier-Ruge W: Neurochemical enzyme changes in Alzheimer's and Pick's disease. Arch Gerontol Geriatr 1984;3:161-165.
42. Harman D: Free radical theory of aging: A hypothesis on pathogenesis of senile dementia of the Alzheimer's type. Age 1991;16:23-30.
43. Linnane AW, Baumer A, Maxwell RJ, Preston H, Zhang C, Marzuki S: Mitochondrial gene mutation: the ageing process and degenerative diseases. Biochem Int 1990;22:1067-1076.
44. Linnane AW, Marzuki S, Ozawa T, Tanaka M: Mitochondrial DNA mutations as an important contribution to aging and degenerative diseases. Lancet 1989;i:642-645.
45. Miquel J: An integrated theory of aging as the result of mitochondrial-DNA mutation in differentiated cells. Arch Gerontol Geriatr 1991; 12:99-117.
46. Ying W: Deleterious network hypothesis of Alzheimer's disease. Med Hypotheses 1996;46: 421-428.
47. Ying W: Deleterious network hypothesis of aging. Med Hypotheses 1997;48:143-148.
48. Ozawa T: Genetic and functional changes in mitochondria associated with aging. Physiol Rev 1997;77:425-464.
49. Corlopassi GA, Shibata D, Soong N-W, Arnheim N: A pattern of accumulation of a somatic deletion of mitochondrial DNA in aging human tissues. Proc Natl Acad Sci USA 1992;89: 7370-7374.
50. Corral-Debrinski M, Hoxton T, Lott MT, Shoffner JM, Beal MF, Wallace DC: Mitochondrial DNA deletion in human brain. Regional variability and increase with advanced age. Nat Genet 1992;2:324-329.
51. Boffoli D, Scacco SC, Bergari R, Solarino G, Santacroce G, Papa S: Decline with age of the respiratory chain activity in human skeletal muscle. Biochim Biophys Acta 1994;1226:73-82.
52. Hsieh RH, Hou JH, Hsu HS, Wei YH: Age-dependent respiratory function decline and DNA deletions in human muscle mitochondria. Biochem Mol Biol Int 1994;32:1009-1022.
53. Schwarze StR, Lee CM, Chung SS, Roecker EB, Weindruch R, Aiken JM: High levels of mitochondrial DNA deletion in skeletal muscle of old rhesus monkeys. Mech Age Dev 1995;83: 91-101.
54. Kalka D, Hoyer S: Long-term cultivation of a neuroblastoma cell line in medium with reduced serum content as a model system of neuronal aging? Arch Gerontol Geriatr 1998;27: 251-268.
55. Gsell W, Conrad R, Hickethier M, Sofie E, Frölich L, Wichart J, Jellinger K, Moll G, Ransmayr G, Beckmann H, Riederer P: Decreased catalase activity but unchanged superoxide dismutase. J Neurochem 1995;64:1216-1223.
56. Browne SE, Beal MF: Oxidative damage and mitochondrial dysfunction in neurodegenerative diseases. Biochem Soc Trans 1994;20: 1002-1006.
57. Nixon RA, Cataldo MA: Free radicals, proteo lysis, and the degeneration of neurons in Alzheimer's disease: How essential is the betaamyloid link? Neurobiol Aging 1994;15:463-469.
58. George-Hyslop PH St, Tanzi RE, Haines JL, Polinsky RJ, Farrer L, Myers RH, Gusella JF: Molecular genetics of familial Alzheimer's disease. Eur Neurol 1989;29 (suppl 3):25-27.
59. Hardy J, Goate A, Owen M, Rossor N: Presenile dementia associated with mosaic trisomy 21 in a patient with a Down syndrome child. Lancet 1989;ii:743.
60. Liddell MB, Bayer AJ, Owen MJ: No evidence that common allclic variation in the amyloid precursor protein (APP) gene confers susceptibility to Alzheimer's disease. Hum Mol Genet 1995;4:853-858.
61. Potter H: Review and hypothesis: Alzheimer's disease and Down syndrome: Chromosome 21 nondisjunction may underlie both disorders. Am J Hum Genet 1991;48:1192-1200.
62. Roses AD: Apolipoprotein E-4 and apolipoprotein E-2 are susceptibility genes that affect the rate of disease expressivity of late-onset familial and sporadic Alzheimer's disease; in Dall JLC, Ermini M, Herrling PL, Meier-Ruge W, Stähelin HB, Staufenbiel M (eds): Adaptations in Aging. London, Academic Press, 1995, pp 171-186.
63. Gibson GE, Peterson C: Aging decreases oxidative metabolism and the release and synthesis of acctylcholine. J Neurochem 1984;37:978-984.
64. Smith GS, de Leon MJ, George AE, Kluger A, Volkow ND, McRae T, Golomb J, Ferris SH, Reisberg B, Ciaravino J: Topography of crosssectional and longitudinal glucose metabolic deficits in Alzheimer's disease. Pathophysiologic implications. Arch Neurol 1992;49:1142-4450.
65. Tucek S, Ricny J: Dolezal V: Advances in the biology of cholinergic neurons. Adv Neurobiol 1990;51:109-115.
66. Dolczal V, Tucek S: Effect of choline and glucose on atropine-induced alterations of acetylcholine synthesis and content in brain of rats. Brain Res 1982;240:285-293.
67. Tucek S: Regulation of acetylcholine synthesis in the brain. J Neurochem 1985;44:11-21.
68. Fibiger HC. Cholinergic mechanisms in learning, memory and dementia: A review of recent evidence. Trends Neurosci 1991;14:2991.
69. Pendlebury WW, Solomon PR: Alzheimer's disease: Therapeutic strategies for the 1990s. Neurobiol Aging 1994;15:287-289.
70. Perry EK, Perry RH, Tomlinson BE, Blessed G, Gibson PH: Gibson PH: Coenzyme A acetylating enzymes in Alzheimer's disease: Possible cholinergic 'compartment' of pyruvate dehydrogcnase. Neurosci Lett 1980;18:105-110.
71. Mountjoy CQ, Rossor MN, Evans NJR. Reynolds GP, Evans H, Roth M. Iverson LL. Emson P: Biochemical and neuropathological changes in the brain and their correlation to the severity of dementia in Alzheimer's disease: in Shagass C, Josiassen RC. Bridger WH, Weiss KJ, Stoff D, Sipsom GM (eds): Biological Psychiatry. New York. Elsevier, 1986, pp 1415-1417.
72. Roth M: Some strategies for tackling the problems of senile dementia and related disorders within the next dceade. Dan Med Bull 1985;35 (suppl 1):92-111.
73. Roder HM, Eden PA, Ingram VM: Brain protein kinasc PK 40 converts TAU into a PHF-like form as found in Alzheimer's disease. Biochem Biophys Res Commun 1993;193:639-647.
74. Blass JP, Baker AC, Ko LW, Black RS: Induction of Alzheimer Antigens by an uncouplcr of oxidative phosphorylation. Arch Neurol 1990; 47:864-869.
75. Gabuzda DH, Bugiciglio J, Cohen LB, Matsudaira P, Yankner BA: Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J Biol Chem 1994;269: 13623-13628.
76. Roder HM, Ingram VM: Two novel kinases phosphorylate tau and the KSP site of heavy neurofilament subunits in high stoichiometric ratios. J Neurosci 1991;11:3325-3343.
77. Selkoe DJ, Polisny MD, Joachim C, Vickcrs EA, Lee G, Fritz LC, Oltersdorf T: Beta-amyloid precursor protein of Alzheimer's disease occurs at 110 to 135 kilodalton membrane-associated proteins in neural and nonneural tissues. Proc Natl Acad Sci USA 1988;85:7341-7345.
78. Koo EH, Sisodia SS, Archer DR, Martin LJ, Weidemann A, Beyreuther K, Fischer P. Masters CL: Precursor of amyloid protein in Alzheimer's disease undergoes fast antcrograde axonal transport. Proc Natl Acad Sci USA 1990; 87:1561-1565.
79. Araki W, Kitaguchi N, Tokushima Y, Ishii K, Aratake H, Shimohama S, Nakamura S. Kumura J: Trophic effect of beta-amyloid precursor protein on cerebral cortical neurons in culture. Biochem Biophys Res Commun 1992; 181:265-271.
80. Caporaso GL, Gandy SE, Buxbaum JD, Ramadhadran TV, Grcengard P: Protein phosphorylation regulates Alzheimer beta/A-4 amyloid precursor protein. Proc Natl Acad Sci USA 1992;89:3055-3059.
81. Fattoretti P, Bertoni-Freddari C, Caselli U, Paoloni R, Meier-Ruge W: Morphological changes in cerebellar mitochondria during aging. Analyt Quantitat Cytol Histol 1996;18: 205-208.
82. Ishiura S: Proteolytic cleavage of Alzheimer's disease amyloid A4 precursor protein. J Neurochem 1991;56:363-369.
83. Tanzi RE, George-Hyslop HP St, Gusella JF: Molecular genetic approaches to Alzheimer's disease. Trends Neurosci 1989;12:152-158.
84. Sisodia SS: β-Amyloid precursor protein cleavage by a membrane-bound protease. Proc Natl Acad Sci USA 1992;89:6075-6079.
85. Saitoh T, Jimoto DS: Altered protein kinase and amyloid β-protein precursor in Alzheimer's disease: Which comes first?; in Boiler F, Rascol A, Christen Y, Kazman R, Signorct JL (eds): Biological Markers of Alzheimer's disease. Berlin, Springer, 1989, pp 103-117.
86. Mann DMA: Pathological correlation of dementia in Alzheimer's disease. Neurobiol Aging 1994;15:357-360.
87. Meier-Ruge W, Hunziker O, Iwangoff P: Senile dementia: A threshold phenomenon of normal aging? A contribution of the functional reserve hypothesis of the brain. Ann NY Acad Sci 1991;621:104-118.
88. Gentleman SM, Greenberg BD, Savage MJ, Noori M, Newman SJ, Roberts GW, Griffin WS, Graham DI: A beta 42 is the predominant form of amyloid beta-protein in the brain of short-term survivors of head injury. Neuroreport 1997;8:1519-1522.
89. Jendroska K, Cervos-Navarro J, Poewe W: Deposition of beta-amyloid associated with cerebral hypoxia (abstract). Clin Neuropathol 1993:12:252.
90. Dodd PR, Scott HL, Westphalen RJ: Excitotoxic mechanisms in the pathogencsis of dementia. Neurochem Int 1994;25:203-219.
91. Roberts GW, Gentleman SM, Lynch A, Murray L, Landon M, Graham DI: Beta amyloid protein deposition in the brain after severe head injury: Implications for the pathogenesis of Alzheimer's disease. J Neurol Neurosurg Psychiatry 1994;57:419-425.
92. Nicoll JA, Roberts GW, Graham DI: Amyloid beta-protein, APOE genotype and head injury. Ann NY Acad Sci 1996;777:271-275.
93. Lee CM, Chung SS, Kaczkowski JM, Weindruch R, Aiken JM: Multiple mitochondrial DNA deletions associated with age in skeletal muscle of rhesus monkeys. J Gerontol Biol Sci 1993;48:B201-B205.
94. Shoulson J: Experimental therapeutics of neurodegenerative disorders: Unmet needs. Science 1998;282:1072-1074.
95. Knusel B, Bao H: Neurotrophins and Alzheimer's disease: Beyond the cholinergic neurons. Life Sci 1996;58:2019-2027.
96. Xu H, Gouras GK, Greenfield JP, Vincent B, Naslund J, Mazzarelli L, Fried G, Jovanovic JN, Seeger M, Relkin NR, Liao F, Checler F, Buxbaum JD, Chait BT, Thinakaran G, Sisodia SS, Wang R, Grcengard P. Gandy S: Estrogen reduces neuronal generation of Alzheimer β-amyloid peptides. Nature Med 1998;4:447-451.